Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 5, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - December 5, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/5/16 - 100 pharma cos join hands with CDSCO, PvPI to frame guidelines for good PvP practices [UMCI News]
Aimed at ushering in good pharmacovigilance practices in the country for drug safety, around 100 pharma companies have joined hands with Central Drugs Standard Control Organisation and Pharmaco-vigilance Programme of India to come up a set of exhaustive guidelines on par with the existing global guidelines. Pharmaco-vigilance programme of India had
12/5/16 - 15 Biggest Mid-Day Gainers For Monday
Biomerica, Inc. shares surged 27.7 percent to $2.68. Neuroderm Ltd shares jumped 26.7 percent to $19.70 as the company disclosed that it will replace two Phase 3 clinical trials with small pharmacokinetic trials following the FDA meeting on ND0612 regulatory development. Stone Energy Corporation gained 23.7 percent to $8.55. Stone Energy shares hav
12/5/16 - 5 Top NASDAQ Biotech Stocks: Select Penny Stocks Climbing
It declined steadily between November 28 and December 2, ending the week 5 percent down that s 148.88 points.. Last week s major gainers on the NASDAQ were:. ESSA Pharma Cogentix Medical Sanofi CTI BioPharma Merus Labs International.
12/5/16 - Abbott Laboratories Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 18, 2016. The SEC file number is 0001179110-16-031866.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form 424B5, Prospectus [Rule 424(B)(5)] (Nov. 17, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 17, 2016. The SEC file number is 0001047469-16-016782.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form 424B5, Prospectus [Rule 424(B)(5)] (Nov. 21, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 18, 2016. The SEC file number is 0001047469-16-016848.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form 8-K, Current Report (Nov. 17, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 17, 2016. The SEC file number is 0001104659-16-157712.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Abbott Laboratories Files SEC Form FWP, Filing Under Securities Act Rules 163/433 of Free Writing Prospectuses (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Abbott Laboratories was posted on November 17, 2016. The SEC file number is 0001104659-16-157893.. A U.S. Securities and Exchange Commission filing i
12/5/16 - Ability to Delay Type 2 Diabetes Disease Progression by Preserving Beta Cell Mass Observed in New Imeglimin Data
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced the presentation of preclinical data supporting Imeglimin s drug profile as a novel diabetes therapy. We are continuing to add further differentiating data to Imeglimin s exciting clinical results as we learn more
12/5/16 - ABPI response to NHS England announcement of 2015/16 Clinical Commissioning policy decisions, including PrEP
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK. Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medi
12/5/16 - Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology
CAMBRIDGE, Mass.& SUMMIT, N.J. Acceleron Pharma Inc. and Celgene Corporation, today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with myelofibrosis at the 58 th Annual Meeting of the American Society of Hematology in San Diego, California. Sotatercept is bei
12/5/16 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on November 18, 2016. The SEC file number is 0001209191-16-151236.. A U.S. Securities and Exchange Commission filing
12/5/16 - Acorda to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties
By a News Reporter-Staff News Editor at Clinical Trials Week Acorda Therapeutics, Inc. announced that the MILESTONE clinical study did not show sufficient efficacy to support further development of dalfampridine to improve post-stroke walking difficulties. I want to express our gratitude to the study participants, their care partners and clinicia
12/5/16 - Adamas Pharmaceuticals Inc. Files SEC Form EFFECT, Notice of Effectiveness (Nov. 22, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on November 22, 2016. The SEC file number is. A U.S. Securities and Exchange Commission filing is a formal doc
12/5/16 - ADIENNE Pharma & Biotech presenting at 58th Annual ASH Meeting with session on Clinical Allogeneic Transplantation
ADIENNE Pharma& Biotech presenting at 58th Annual ASH Meeting with session on Clinical Allogeneic Transplantation. Lugano, December 5, 2016; ADIENNE Pharma& Biotech SA, an integrated biopharmaceutical group of companies based in Switzerland, announced that leading experts in the field of onco-hematology and bone marrow transplantation today have...
12/5/16 - Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD
Aduro Biotech, Inc., a biopharmaceutical company with three distinct immunotherapy technologies, announced today that an anti-CD27 antibody developed by Aduro Biotech Europe and derived from its proprietary B-select technology has been selected to be advanced into clinical development by Merck& Co., Inc., Kenilworth, NJ, USA, through a subsidiary
12/5/16 - Aegerion Pharmaceuticals, a Subsidiary ofNovelionTherapeutics, Enters into Agreement in Principle to Settle Class Action Shareholder Lawsuit
Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsidiary of Novelion, entered into an agreement in principle to settle all claims in the class action shareho
12/5/16 - Agios Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Nov. 18, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on November 18, 2016. The SEC file number is 0001193125-16-771481.. A U.S. Securities and Exchange Commission f
12/5/16 - AGTC to Present at Upcoming Conferences
Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies for the treatment of rare diseases, today announced its participation in upcoming conferences.. Genetic Rx Boston, Mass. AGTC President& CEO Sue Washer will be moderating a panel discussion entitled
12/5/16 - Alembic Pharma gets US FDA nod for anti-migraine drug [Cyprus Mail]
Alembic Pharmaceuticals has received approval from the US health regulator for Zolmitriptan orally disintegrating tablets, used for the treatment of migraine, in the American market. The company has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets, 2.5
12/5/16 - Alembic Pharmaceuticals gets USFDA approval for Zolmitriptan Orally Disintegrating Tablets [India Infoline News Service]
Alembic now has a total of 51 ANDA approvals from USFDA. Alembic Pharmaceuticals Limited announced that the company has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets, 2.5 mg and 5 mg. Alembic Pharmaceuticals Ltd is currently trading at Rs 631.9, down b
12/5/16 - Alembic Pharmaceuticals Ltd drops 1.23% [India Infoline News Service]
Alembic Pharmaceuticals Limited announced that the company has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application for Zolmitriptan Orally Disintegrating Tablets. Alembic Pharmaceuticals Ltd ended at Rs 624.45 down by Rs 7.80 or 1.23% from its previous closing of Rs 632.25 on the BSE. The scrip opened at
12/5/16 - Alimera Sciences Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Nov. 17, 2016)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alimera Sciences Inc. was posted on November 17, 2016. The SEC file number is 0000935836-16-001192.. A U.S. Securities and Exchange Commission filing
12/5/16 - Allergan PLC Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important Deadline in Class...
By a News Reporter-Staff News Editor at Pharma Business Week Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan plc and/or Actavis plc between February 25, 2014 and November 3, 2016, both dates inclusive of the important January 3, 2017 lead plaintiff deadline in the class action filed by the firm.
12/5/16 - Allergan's Trademark Application for "SERISCAFFOLD" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SERISCAFFOLD" by Susan J. Hinchey, representing Allergan. The owner/registrar information for this application is: Susan J. Hinchey, Allergan, 2525 Dupont Dri
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415